Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure
Top Cited Papers
- 1 June 2001
- journal article
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 7 (2), 176-182
- https://doi.org/10.1054/jcaf.2001.25652
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Current perspectives on the design of phase II trials of new drugs for the treatment of heart failureAmerican Heart Journal, 2000
- Randomised study of effect of ibopamine on survival in patients with advanced severe heart failureThe Lancet, 1997
- Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart FailureCirculation, 1996
- Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failureThe American Journal of Cardiology, 1996
- Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failureEuropean Heart Journal, 1994
- Role of surrogate end points in the evaluation of drugs for heart failureJournal of the American College of Cardiology, 1993
- Spectrum and outcome of congestive heart failure in a hospitalized populationAmerican Heart Journal, 1993
- The effects of oral ibopamine in patients with mild heart failure — a double blind placebo controlled comparison to furosemideInternational Journal of Cardiology, 1993
- The placebo effect in heart failureAmerican Heart Journal, 1990
- How should we judge the efficacy of drug therapy in patients with chronic congestive heart failure? The insights of six blind menJournal of the American College of Cardiology, 1987